📊 SER Key Takeaways
Is Serina Therapeutics, Inc. (SER) a Good Investment?
Serina Therapeutics exhibits classic early-stage biotech distress with $130K revenue against $6.9M operating losses, providing only ~1.3 years of cash runway at current burn rates. While the 78.5% gross margin suggests product viability, the company faces an existential challenge of scaling revenue from near-zero levels or securing dilutive capital before cash depletion. The lack of profitability pathways and negative unit economics make this a speculative survival story with high probability of value destruction.
Serina Therapeutics, Inc. Key Strengths (SER)
- Strong liquid cash position of $24.5M (90% of assets) provides near-term operational runway
- Positive gross margin of 78.5% indicates underlying product economics and pricing power
- Sequential revenue growth of 132% YoY demonstrates initial market traction despite minimal base
SER Stock Risks: Serina Therapeutics, Inc. Investment Risks
- Severe cash burn of $4.6M quarterly with only ~1.3 years remaining runway at current rate
- Extreme operating loss of $6.9M on $130K revenue (6,900% loss-to-revenue ratio) indicates unsustainable unit economics
- Early-stage biotech with minimal commercial revenue faces regulatory, market adoption, and capital adequacy risks
- Negative interest coverage ratio (-69.6x) and $11.2M long-term debt burden jeopardize financial stability
- Operating expenses exceed revenue by 53x magnitude, requiring exponential revenue acceleration or restructuring
Key Metrics to Watch
- Quarterly sequential revenue growth trajectory and path to material commercial scale
- Monthly cash burn rate trend and revised runway estimates
- Operating expense control and gross margin sustainability as revenue scales
- Clinical pipeline advancement, FDA approvals, and product launch milestones
- Capital raise necessity and dilution impact within next 12-18 months
Serina Therapeutics, Inc. (SER) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.18x current ratio provides a solid financial cushion.
SER Profit Margin, ROE & Profitability Analysis
SER vs Healthcare Sector: How Serina Therapeutics, Inc. Compares
How Serina Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Serina Therapeutics, Inc. Stock Overvalued? SER Valuation Analysis 2026
Based on fundamental analysis, Serina Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Serina Therapeutics, Inc. Balance Sheet: SER Debt, Cash & Liquidity
SER Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Serina Therapeutics, Inc.'s revenue has declined by 64% over the 5-year period, indicating business contraction. The most recent EPS of $-1.51 indicates the company is currently unprofitable.
SER Revenue Growth, EPS Growth & YoY Performance
SER Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $1.4M | $0.13 |
| Q2 2025 | $51.0K | $5.2M | $0.51 |
| Q1 2025 | N/A | -$4.8M | $-0.49 |
| Q3 2024 | $14.0K | $1.4M | $0.13 |
| Q2 2024 | $7.0K | $808.0K | $0.11 |
| Q1 2024 | $5.0K | $1.7M | $0.20 |
| Q3 2023 | $9.0K | -$2.4M | $-0.06 |
| Q2 2023 | $9.0K | -$2.6M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Serina Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SER SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Serina Therapeutics, Inc. (CIK: 0001708599)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 27, 2026 | 4 | xslF345X06/wk-form4_1779911715.xml | View → |
| May 26, 2026 | 4 | xslF345X06/wk-form4_1779839080.xml | View → |
| May 26, 2026 | 4 | xslF345X06/wk-form4_1779838635.xml | View → |
| May 26, 2026 | 4 | xslF345X06/wk-form4_1779838527.xml | View → |
| May 26, 2026 | 4 | xslF345X06/wk-form4_1779838407.xml | View → |
❓ Frequently Asked Questions about SER
What is the AI rating for SER?
Serina Therapeutics, Inc. (SER) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SER's key strengths?
Claude: Strong liquid cash position of $24.5M (90% of assets) provides near-term operational runway. Positive gross margin of 78.5% indicates underlying product economics and pricing power.
What are the risks of investing in SER?
Claude: Severe cash burn of $4.6M quarterly with only ~1.3 years remaining runway at current rate. Extreme operating loss of $6.9M on $130K revenue (6,900% loss-to-revenue ratio) indicates unsustainable unit economics.
What is SER's revenue and growth?
Serina Therapeutics, Inc. reported revenue of $130.0K.
Does SER pay dividends?
Serina Therapeutics, Inc. does not currently pay dividends.
Where can I find SER SEC filings?
Official SEC filings for Serina Therapeutics, Inc. (CIK: 0001708599) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SER's EPS?
Serina Therapeutics, Inc. has a diluted EPS of $-0.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SER's fundamental grade?
Based on our AI fundamental analysis in June 2026, Serina Therapeutics, Inc. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SER stock overvalued or undervalued?
Valuation metrics for SER: ROE of -39.1% (sector avg: 15%), net margin of -5,306.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SER's AI grade for 2026?
Our dual AI analysis gives Serina Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SER's free cash flow?
Serina Therapeutics, Inc.'s operating cash flow is $-4.6M, with capital expenditures of $25.0K. FCF margin is -3,533.1%.
How does SER compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,306.2% (avg: 12%), ROE -39.1% (avg: 15%), current ratio 4.18 (avg: 2).